Drug delivery is the science of getting a medication to the right place in the body, at the right concentration, and for the right amount of time. It sounds straightforward, but the human body treats nearly every foreign molecule as a threat and has evolved elaborate defenses to neutralize or expel them. The result is that many drugs that work perfectly in a lab dish fail spectacularly inside a living person, not because the chemistry is wrong, but because the drug never reaches its target in useful amounts. From the lipid nanoparticles that made mRNA vaccines possible to dissolving microneedles and bacteria genetically programmed to release therapeutics on command, the field has become one of the most inventive corners of modern medicine.
Why Most of a Drug Never Reaches Its Target
When you swallow a pill, you might assume the active ingredient travels directly to wherever it is needed. In reality, a drug taken by mouth faces a gauntlet. It must survive the acidic environment of the stomach, cross the intestinal lining into the bloodstream, and then pass through the liver before it can circulate to the rest of the body. That liver pass, known as first-pass metabolism, can chemically dismantle a large fraction of the drug before it ever has a chance to do its job. Oral bioavailability depends on three things: how much drug gets absorbed through the gut wall, how much survives the gut wall’s own enzymes, and how much escapes the liver’s processing.
Some compounds are hit especially hard. Certain plant-derived molecules and protein-based drugs undergo extensive breakdown by liver enzymes, resulting in very poor oral bioavailability and limited therapeutic effect.1PubMed Central. First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics For large biological molecules like insulin and antibodies, the situation is even worse. The acidic stomach and protein-digesting enzymes of the gastrointestinal tract destroy most proteins before they can be absorbed, which is why these drugs are typically given by injection rather than as a pill.2PubMed Central. Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies Designing oral formulations that can protect fragile biological drugs through this journey remains one of the field’s persistent challenges.
The Blood-Brain Barrier and Other Biological Walls
Even after a drug successfully enters the bloodstream, reaching certain organs is another story. The brain is the most notorious example. It is surrounded by the blood-brain barrier, a tightly sealed layer of cells lining the brain’s blood vessels. This barrier is extraordinarily selective, blocking the vast majority of molecules from crossing into the central nervous system. While this is critical for protecting the brain from toxins and infections, it also blocks nearly all conventional drug molecules from getting in, making treatment of neurological diseases like Alzheimer’s, Parkinson’s, and brain cancers enormously difficult.3PubMed Central. Drug Delivery Across the Blood-Brain Barrier: A New Strategy for the Treatment of Neurological Diseases
The eye presents a similar challenge. The cornea, conjunctiva, and blood-retinal barrier work together to keep foreign substances out of the interior of the eye, which means that getting drugs to the retina (for conditions like macular degeneration) often requires direct injection into the eyeball. These injections are effective but uncomfortable and carry infection risks, so patients typically need repeated treatments over months or years.4PubMed. Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases Drug delivery researchers are working on nanocarriers and sustained-release implants that could reduce the frequency of these injections.
Lipid Nanoparticles and the mRNA Breakthrough
The COVID-19 mRNA vaccines brought lipid nanoparticles into the spotlight, but these tiny fat-based carriers have been studied for decades. A lipid nanoparticle, or LNP, wraps a fragile molecule like mRNA inside a shell of specialized fats that protect it during transit through the bloodstream and help it enter cells. The key trick is what happens once the LNP is inside a cell. After a cell absorbs the particle, it ends up in a small internal compartment called an endosome. Getting out of that compartment and into the cell’s main interior, where the mRNA can actually be read and translated into a protein, is one of the biggest technical hurdles in the field.
Recent research has shed light on how this escape works. The LNP’s lipids contain ionizable components that change their behavior when exposed to the acidic environment inside the endosome, which destabilizes the compartment’s membrane. One reevaluation of the data suggests that LNPs escape through a mechanism involving the budding and collapse of small vesicles within the endosome, after which the released genetic material forms an insoluble clump inside the cell. The slow dissolving of that clump may itself be a bottleneck that limits how efficiently the delivered mRNA gets translated into protein.5PubMed Central. Endosomal Escape of Lipid Nanoparticles: A Perspective on the Literature Data Researchers have also found that the internal structure of the LNP itself, specifically how its lipids rearrange into ordered geometric phases as they become ionized, correlates with how well the particle delivers its cargo.6PubMed. Ionizable Lipid Nanoparticles for mRNA Delivery: Internal Self-Assembled Inverse Mesophase Structure and Endosomal Escape Understanding these details matters because even small improvements in endosomal escape efficiency could dramatically increase the potency of mRNA therapies, potentially lowering required doses and reducing side effects.
Why Nanoparticles Have Not Yet Cured Cancer
For years, one of the big selling points of nanoparticle-based cancer drugs was the enhanced permeability and retention (EPR) effect. Tumors tend to have leaky blood vessels and poor drainage, so the idea was that nanoscale drug carriers would naturally accumulate in tumors at much higher levels than in healthy tissue. This concept drove enormous investment. The reality, however, has been sobering. While nanoparticles do preferentially leak into tumor tissue through those permeable vessels, the actual concentration advantage over critical normal organs is less than twofold, which in most cases is not enough to cure the cancer.7PubMed Central. Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
This does not mean nanoparticles are useless in oncology, but it has forced the field to move beyond passive accumulation toward more active targeting strategies. One mature approach is the antibody-drug conjugate, or ADC, which links a powerful chemotherapy molecule to an antibody that recognizes a specific protein on the surface of cancer cells. Preclinical studies have shown that this design concentrates free drug inside the tumor while largely sparing non-target tissues from chemotherapy exposure. Several ADCs have reached the clinic, including treatments for lymphoma and breast cancer.8PubMed Central. Antibody-drug conjugates: targeted drug delivery for cancer
Sustained Release and the Power of Polymers
Sometimes the problem is not where a drug goes but how quickly it leaves. Many medications are cleared from the body within hours, meaning patients have to take multiple doses per day to maintain a therapeutic level. Sustained-release systems aim to solve this by packaging a drug inside a material that degrades slowly, releasing the medication over days, weeks, or even months.
The workhorse material for this approach is a polymer called PLGA, which stands for poly lactic-co-glycolic acid. It is biocompatible, meaning the body tolerates it well, and biodegradable, meaning it breaks down into harmless byproducts over time. It has been approved by the FDA for use in humans and has been extensively studied for delivering everything from small-molecule drugs to proteins and larger biological molecules.9PubMed Central. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier By adjusting the ratio of its two component acids and the size of the particles, researchers can tune how fast the polymer erodes and therefore how quickly the drug is released.10PubMed Central. Poly(lactic-co-glycolic) acid-controlled-release systems: experimental and modeling insights PLGA-based products are already on the market for conditions like prostate cancer and schizophrenia, where a single injection can provide steady medication levels for a month or longer.
Delivering Drugs Through the Skin
Patches that deliver drugs through the skin have been around for decades. Nicotine patches and pain patches are familiar examples. But conventional patches work only for a small set of drugs whose molecules are tiny enough to passively diffuse through the skin’s outer layer, which is an excellent barrier against most substances.
Microneedles are designed to get around that limitation. These are arrays of extremely small projections, typically less than a millimeter tall, that pierce the outermost skin layer without reaching the nerve endings deeper down, so they are not particularly painful. Early work focused on solid microneedles that poke temporary holes in the skin to increase its permeability, and studies showed this worked for delivering molecules ranging from small drugs to nanoparticles, and even insulin and vaccines in animal models.11PubMed. Microneedles for transdermal drug delivery
A more recent design uses dissolving microneedles made from water-soluble, biocompatible materials. The drug is encapsulated directly within the needle shaft, and once inserted into the skin, the needles dissolve within minutes, releasing their cargo. This leaves no sharp medical waste behind. Researchers have demonstrated that molecules encapsulated in these dissolving needles retain their biological activity, with one study showing that a test enzyme kept nearly all of its function even after two months of storage at room temperature. By loading drug into the backing material rather than just the needle tips, they also achieved sustained release over hours to days.12PubMed Central. Dissolving microneedles for transdermal drug delivery Dissolving microneedle patches for vaccines are now in clinical development, with the potential to simplify mass immunization campaigns by eliminating the need for trained injectors and cold storage.
The Nose-to-Brain Shortcut
One creative way around the blood-brain barrier is to skip the bloodstream entirely and go through the nose. The nasal cavity is directly connected to the brain through the olfactory nerve (responsible for smell) and the trigeminal nerve (responsible for facial sensation). Drugs sprayed into the upper part of the nose can travel along these nerve pathways and reach the brain without ever needing to cross the blood-brain barrier.13PubMed. Mechanism of intranasal drug delivery directly to the brain This nose-to-brain route is noninvasive, which is a major advantage over other strategies for brain delivery that require surgery or disruptive techniques to temporarily open the barrier.14PubMed Central. Nose-to-brain drug delivery: from bench to bedside
The approach has limitations. The nasal cavity has a small surface area, mucus clearance constantly washes material away, and the amount of drug that actually reaches the brain is still relatively low. Researchers are combining intranasal delivery with nanoparticle carriers and mucoadhesive formulations to try to improve absorption and extend contact time. Several intranasal products are already on the market for acute conditions like seizure rescue and migraine, and the approach is gaining momentum for chronic neurodegenerative diseases where sustained brain exposure is needed.15International Journal of Pharmaceutics: X. Intranasal drug delivery: Unlocking the nose-to-brain route for central nervous system therapies
Smart Materials That Respond to Their Surroundings
One of the more elegant developments in drug delivery is the creation of materials that release their payload only when they sense a specific signal from the body. The most widely studied trigger is pH. Tumors tend to be slightly more acidic than healthy tissue because of their altered metabolism, and researchers have designed polymer-based carriers that remain stable at the normal blood pH of about 7.4 but break apart or swell in the lower-pH environment around and inside tumors, releasing their drug cargo precisely where it is needed.16PubMed Central. pH-Responsive Polymer Nanomaterials for Tumor Therapy Beyond pH, the tumor microenvironment also features elevated levels of reactive oxygen species, low oxygen, and distinctive enzyme activity, all of which can serve as triggers for drug release.17PubMed Central. Tumor Microenvironment-Responsive Drug Delivery Based on Polymeric Micelles for Precision Cancer Therapy: Strategies and Prospects
External physical triggers are another option. Ultrasound-activated microbubbles, originally developed as contrast agents for imaging, have been repurposed as drug delivery vehicles. When exposed to focused ultrasound waves, the microbubbles oscillate and can temporarily increase the permeability of nearby blood vessel walls, pushing drug molecules into surrounding tissue. The technique has been explored for delivering drugs across the blood-brain barrier and deep into solid tumors, and after roughly three decades of research it has moved into early clinical trials.18PubMed Central. Design of pH-Responsive Nanomaterials Based on the Tumor Microenvironment
Implantable Depots and Living Drug Factories
For some conditions, particularly localized cancers that have been surgically removed but carry a risk of recurrence, implanting a drug-releasing device directly at the treatment site is an attractive idea. Injectable hydrogels are one version of this. These are gel-like materials that can be loaded with drug-carrying nanoparticles and injected as a liquid, then solidify in place under body conditions. One research group demonstrated a hydrogel system imbibed with drug-loaded nanoparticles that formed a stable gel depot under the skin and released an anticancer drug over a prolonged period without causing toxicity to surrounding organs.19PubMed. Injectable hydrogel imbibed with camptothecin-loaded mesoporous silica nanoparticles as an implantable sustained delivery depot for cancer therapy Other implantable formats under investigation include nanofibers, thin films, wafers, and osmotic pumps, each with distinct release profiles that can be tailored for different clinical needs.20PubMed Central. Exploring the vast potentials and probable limitations of novel and nanostructured implantable drug delivery systems for cancer treatment
Perhaps the most futuristic-sounding approach involves using genetically engineered bacteria as living drug factories. Bacteria can be programmed with synthetic gene circuits so that they home in on a specific tissue, sense local conditions, and produce and release therapeutic molecules on demand.21PubMed Central. Programmable microbial therapeutics: advances in engineered bacteria for targeted in vivo delivery and precision medicine The concept has been demonstrated in practice. One team developed an implantable hydrogel material that encapsulates engineered bacteria within a tough scaffold. The material kept bacteria fully contained for six months, withstood the mechanical stresses of being inside a living body, and allowed the embedded microbes to sense their environment and release therapeutics on demand. In a mouse model of prosthetic joint infection, the system autonomously detected the infection and treated it.22PubMed. Implantable living materials autonomously deliver therapeutics using contained engineered bacteria The safety question with living therapeutics is obvious and serious, but containment strategies are advancing rapidly.
Exosomes and Biological Nanocarriers
Cells naturally communicate by releasing tiny membrane-enclosed packages called exosomes, which shuttle proteins, genetic material, and other molecules between cells. Researchers have recognized these as readymade drug delivery vehicles. Exosomes are roughly 30 to 150 nanometers across and come with built-in advantages over synthetic nanoparticles: the body tends to tolerate them well because they look like the body’s own material, they provoke less immune reaction, and they appear to be less toxic.23PubMed Central. Exosome-Based Drug Delivery: Translation from Bench to Clinic
The appeal is clear, but turning exosomes into practical medicines is not easy. They are difficult to produce in large, standardized quantities, and loading them efficiently with a drug of choice remains a technical challenge. Surface modifications can improve their ability to target specific tissues, and modified exosomes have shown promise in preclinical models for treating brain disorders, tumors, and liver disease.24PubMed Central. Extracellular vesicles for targeted drug delivery: advances in surface modification strategies and therapeutic applications The field is still in early stages, but several exosome-based therapies are now in clinical trials.
The Protein Corona Problem
One complication that cuts across nearly all nanoparticle-based delivery systems is something called the protein corona. The moment a nanoparticle enters the bloodstream, blood proteins rapidly coat its surface, forming a layer that changes everything about how the particle interacts with the body. This corona can alter how cells take up the particle, affect its toxicity, change whether it triggers an immune response, and even interfere with drug release. Researchers have found that the corona’s effects depend on the type of nanoparticle: in one study, protein-coated nanogels triggered a marked increase in inflammatory signaling from human immune cells, an effect that was not seen with protein-coated solid nanoparticles of similar composition.25PubMed. Protein Corona Formation on Colloidal Polymeric Nanoparticles and Polymeric Nanogels: Impact on Cellular Uptake, Toxicity, Immunogenicity, and Drug Release Properties This means that a nanoparticle designed and tested under clean laboratory conditions may behave very differently once it encounters real blood, and the field is only beginning to grapple with how to predict and control these interactions.
Why So Few Nanomedicines Reach the Market
Given how active the drug delivery research community is, a reasonable question is why relatively few advanced delivery systems have made it to pharmacy shelves. Scaling up is a major hurdle. Techniques that produce beautiful, uniform nanoparticles in a university lab may fall apart when a manufacturer tries to make them by the kilogram under conditions that meet pharmaceutical quality standards.26PubMed Central. Nanomedicine scale-up technologies: feasibilities and challenges
Regulation is the other bottleneck. Nanomedicines are structurally complex, and their properties depend on factors like particle size distribution, surface chemistry, and internal architecture in ways that are difficult to fully characterize using standard analytical methods. This creates problems when generic manufacturers want to create follow-on versions of an approved nanomedicine. The conventional generic drug approval pathway, which relies on showing that a copy is chemically identical and behaves the same way in the blood, does not work well for these products because small differences in manufacturing can produce particles that look similar on paper but behave differently in the body.27PubMed. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach? Regulators have had to develop new, more nuanced frameworks that require side-by-side quality, preclinical, and clinical comparisons rather than simple chemical equivalence.28PubMed. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars
Inhaled Drug Delivery and the Challenge of Lung Deposition
Delivering drugs directly to the lungs is a natural fit for respiratory diseases like asthma and chronic obstructive pulmonary disease, but inhaled delivery is also being explored as a route for systemic drugs and vaccines. The lungs offer a huge surface area, thin tissue barriers, and rich blood supply, making them an efficient absorption site. The challenge is consistency. Dry powder inhalers, the most common delivery devices, often deliver unpredictable amounts of drug to the deep lungs, where absorption happens. Particle size, the patient’s breathing pattern, humidity, and the device’s internal design all affect how much drug actually reaches its target versus getting deposited in the mouth and throat or exhaled back out.29PubMed Central. Dry powder inhaler design and particle technology in enhancing Pulmonary drug deposition: challenges and future strategies Improving the reproducibility of lung deposition is an active area of particle engineering research, with strategies including engineered particle shapes, carrier particles, and device innovations that reduce dependence on the patient’s inhalation technique.